These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8873219)

  • 1. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population.
    Jurima-Romet M; Goldstein JA; LeBelle M; Aubin RA; Foster BC; Walop W; Rode A
    Pharmacogenetics; 1996 Aug; 6(4):329-39. PubMed ID: 8873219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population.
    Kubota T; Chiba K; Ishizaki T
    Clin Pharmacol Ther; 1996 Dec; 60(6):661-6. PubMed ID: 8988068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
    Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
    Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
    Brøsen K; de Morais SM; Meyer UA; Goldstein JA
    Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
    Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
    Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
    Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M
    Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation.
    Brockmöller J; Rost KL; Gross D; Schenkel A; Roots I
    Pharmacogenetics; 1995 Apr; 5(2):80-8. PubMed ID: 7663532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
    He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
    Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.
    De Morais SM; Wilkinson GR; Blaisdell J; Meyer UA; Nakamura K; Goldstein JA
    Mol Pharmacol; 1994 Oct; 46(4):594-8. PubMed ID: 7969038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese.
    Takakubo F; Kuwano A; Kondo I
    Pharmacogenetics; 1996 Jun; 6(3):265-7. PubMed ID: 8807668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population.
    de Morais SM; Goldstein JA; Xie HG; Huang SL; Lu YQ; Xia H; Xiao ZS; Ile N; Zhou HH
    Clin Pharmacol Ther; 1995 Oct; 58(4):404-11. PubMed ID: 7586932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.
    Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y
    Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
    Goldstein JA; Ishizaki T; Chiba K; de Morais SM; Bell D; Krahn PM; Evans DA
    Pharmacogenetics; 1997 Feb; 7(1):59-64. PubMed ID: 9110363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.
    Xiao ZS; Goldstein JA; Xie HG; Blaisdell J; Wang W; Jiang CH; Yan FX; He N; Huang SL; Xu ZH; Zhou HH
    J Pharmacol Exp Ther; 1997 Apr; 281(1):604-9. PubMed ID: 9103550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
    Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population.
    Xie HG; Huang SL; Xu ZH; Xiao ZS; He N; Zhou HH
    Pharmacogenetics; 1997 Apr; 7(2):115-9. PubMed ID: 9170148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.
    Xie HG; Kim RB; Stein CM; Wilkinson GR; Wood AJ
    Br J Clin Pharmacol; 1999 Sep; 48(3):402-8. PubMed ID: 10510153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotype analysis of cytochrome P450 2C19 in Chinese subjects with mephenytoin S/R enantiomeric ratio in urine measured by chiral GC.
    Yao TW; Zeng S; Wang TW; Chen SQ
    Biomed Chromatogr; 2001 Feb; 15(1):9-13. PubMed ID: 11180294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose.
    Feng HJ; Huang SL; Wang W; Zhou HH
    Br J Clin Pharmacol; 1998 Jan; 45(1):27-9. PubMed ID: 9489590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
    Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
    Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.